Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.
KIRhub 2.0· v2
Ependymoma Hub
V1V2
Sign in
← Cases

Bosutinib

6a96cbad-065f-5e1d-a091-c0aa55be7ce1 · FDA Approved · targets BCR_ABL, ABL1, ABL2_ARG

Bosutinib

MeasuredReference

Bosutinib targets TNK2, BLK, C_SRC. Strongest hallmark effect: tumor promoting inflammation.

Primary targets

TNK2BLKC_SRCFRK_PTK5KHS_MAP4K5

Top hallmarks

  • tumor promoting inflammation6.5k
  • evading apoptosis5.4k
  • proliferation5.1k

Top pathways disrupted

  • apical junction12.9k
  • allograft rejection12.5k
  • pi3k akt mtor signaling12.0k

Resistance landscape — Bosutinib

MeasuredReference

No variant annotations found on Bosutinib's top targets.

No variant annotations on Bosutinib's top targets.
Open in new tab